---
$id: https://graph.org.ai/products/commodity/51313801
$type: Product
source: UNSPSC
code: "51313801"
title: "Fexofenadine"
class: "51313800"
classTitle: "Antihistamine or H1 blocker terfenadine/analogs and derivatives"
family: "51310000"
familyTitle: "Antihistamines or H1 blockers"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Fexofenadine

**UNSPSC Code**: 51313801
**Class**: [Antihistamine or H1 blocker terfenadine/analogs and derivatives](Antihistamine or H1 blocker terfenadineanalogs and derivatives.mdx)
**Family**: [Antihistamines or H1 blockers](../Antihistamines or H1 blockers.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H39NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E6582LOH6V, chemically known as 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid but generally known as fexofenadine, which bears US NIH Compound Identifier 3348. European Medicines Agency schedules Fexofenadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13883MIG. The term FEXOFENADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules fexofenadine in its Anatomical Therapeutic Chemical (ATC) Classification. FEXOFENADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fexofenadine under HS 29333999 and SITC 51574. As of Q4 2014, FEXOFENADINE remains the US FDA Preferred Term for this commodity. Fexofenadine bears US NLM identifiers UMLS ID C0296800 and NCI Concept Code C61764. SMILES: OC(C1CCN(CC1)CCCC(O)C1CCC(C(C)(C)C(=O)O)CC1)(C1CCCCC1)C1CCCCC1.

